HPV E6/E7 mRNA检测在宫颈癌筛查分流管理中的价值与应用策略

doi:10.11958/20260725

天津医药 ›› 2026, Vol. 54 ›› Issue (9): 1003-1008.doi: 10.11958/20260725

• 综述 • 上一篇

HPV E6/E7 mRNA检测在宫颈癌筛查分流管理中的价值与应用策略

刘洁¹^,²(), 刘耘畅²^,³, 燕丽晨²^,³, 王轶琳²^,^△()

¹ 内蒙古科技大学包头医学院（邮编014040）
² 内蒙古自治区人民医院妇产科（邮编014040）
³ 内蒙古医科大学（邮编014040）

收稿日期:2026-03-16 修回日期:2026-05-08 出版日期:2026-09-15 发布日期:2026-09-14
通讯作者: ^△E-mail：blueangel1214@163.com
作者简介:刘洁（1999），女，硕士在读，主要从事妇科肿瘤方面研究。E-mail：1052392696@qq.com
基金资助:
公立医院科研联合基金科技项目(2023GLLH0085)

Stratification value and application strategies of HPV E6/E7 mRNA testing in cervical cancer screening

LIU Jie¹^,²(), LIU Yunchang²^,³, YAN Lichen²^,³, WANG Yilin²^,^△()

¹ Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014040, China
² Department of Obstetrics and Gynecology, Inner Mongolia People's Hospital 014040, China
³ Inner Mongolia Medical University 014040, China

Received:2026-03-16 Revised:2026-05-08 Published:2026-09-15 Online:2026-09-14
Contact: ^△E-mail：blueangel1214@163.com

刘洁, 刘耘畅, 燕丽晨, 王轶琳. HPV E6/E7 mRNA检测在宫颈癌筛查分流管理中的价值与应用策略[J]. 天津医药, 2026, 54(9): 1003-1008.

LIU Jie, LIU Yunchang, YAN Lichen, WANG Yilin. Stratification value and application strategies of HPV E6/E7 mRNA testing in cervical cancer screening[J]. Tianjin Medical Journal, 2026, 54(9): 1003-1008.

摘要/Abstract

摘要：

随着宫颈癌发病机制研究的深入及宫颈癌多种筛查手段的发展，人乳头瘤病毒（HPV）E6/E7 mRNA检测通过靶向病毒癌基因的转录活性，直接反映HPV的致癌潜能与病毒整合状态，推动了宫颈癌筛查策略从单纯“发现感染”向精准“评估风险”的范式转型。该文系统综述了HPV E6/E7 mRNA检测的分子基础、技术特征、诊断效能及筛查分流应用，探讨其动态监测在癌前病变分层管理中的价值及面临的临床挑战，为宫颈癌的精准防控与医疗资源优化提供参考。

关键词: 乳头状瘤病毒科, 宫颈上皮内瘤样病变, 宫颈肿瘤, E6/E7 mRNA, 风险分层

Abstract:

With the deepening understanding of the pathogenesis of cervical cancer and the development of diverse screening modalities for cervical cancer, the detection of human papillomavirus (HPV) E6/E7 mRNA targets the transcriptional activity of viral oncogenes, directly reflects the carcinogenic potential and viral integration status of HPV, driving a paradigm shift in cervical cancer screening strategies from merely "detecting infection" to precisely "assessing risk". This article systematically reviews the molecular basis, technical characteristics, diagnostic performance and triage application of HPV E6/E7 mRNA testing, explores its value in dynamic monitoring for risk-stratified management of precancerous lesions and the clinical challenges encountered, and provides insights for precision prevention and control of cervical cancer and optimization of healthcare resources.

Key words: papillomaviridae, cervical intraepithelial neoplasia, uterine cervical neoplasms, E6/E7 mRNA, risk stratification

中图分类号:

R711.74

图/表 1

参考文献 38

[1]	Pruski D, Millert-Kalińska S, Wszołek K, et al. Analysis of molecular markers of HPV infection persistence:a narrative review[J]. Cancers(Basel), 2026, 18(6):981. doi:10.3390/cancers18060981.
[2]	Wang J, Wang L, Bu F, et al. Comparative performance of standalone E6/E7 mRNA testing versus a combined DNA genotyping and viral load assay for detecting cervical high-grade lesions:a retrospective paired study[J]. Am J Transl Res, 2026, 18(1):842-859. doi:10.62347/WNNZ7362.
[3]	Brant A C, Menezes A N, Felix S P, et al. Characterization of HPV integration,viral gene expression and E6E7 alternative transcripts by RNA-Seq:a descriptive study in invasive cervical cancer[J]. Genomics, 2019, 111(6):1853-1861. doi:10.1016/j.ygeno.2018.12.008.
[4]	Zhang Y, Qiu K, Ren J, et al. Roles of human papillomavirus in cancers:oncogenic mechanisms and clinical use[J]. Signal Transduct Target Ther, 2025, 10(1):44. doi:10.1038/s41392-024-02083-w.
[5]	Zhou L, Qiu Q, Zhou Q, et al. Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer[J]. Nat Commun, 2022, 13(1):2563. doi:10.1038/s41467-022-30190-1.
[6]	Varesano S, Ciccarese G, Paudice M, et al. Evaluating HPV viral load and multiple infections for enhanced cervical cancer risk-based assessment[J]. Life(Basel), 2025, 15(2):153. doi:10.3390/life15020153.
[7]	WHO. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention,second edition[M]. Geneva: World Health Organization, 2021,6-7.
[8]	Kafasi A, Pitiriga V C, Spanakis N, et al. Evaluation of the pretect HPV-proofer E6/E7 mRNA assay for the detection of precancerous cervical lesions in the Greek female population[J]. Pathogens, 2025, 14(9):853. doi:10.3390/pathogens14090853.
[9]	Baranda-Ávila N, Maldonado G, Vélez D E, et al. Translational regulation of human papillomavirus mRNAs in carcinogenesis: old questions and new insights[J]. Front Cell Dev Biol, 2025, 13:1676001. doi:10.3389/fcell.2025.1676001.
[10]	Tian R, Huang Z, Li L, et al. HPV integration generates a cellular super-enhancer which functions as ecDNA to regulate genome-wide transcription[J]. Nucleic Acids Res, 2023, 51(9):4237-4251. doi:10.1093/nar/gkad105.
[11]	Li J, Li S. From viral infection to genome reshaping:The triggering role of HPV integration in cervical cancer[J]. Int J Mol Sci, 2025, 26(18):9214. doi:10.3390/ijms26189214.
[12]	Karimzadeh M, Arlidge C, Rostami A, et al. Human papillomavirus integration transforms chromatin to drive oncogenesis[J]. Genome Biol, 2023, 24(1):142. doi:10.1186/s13059-023-02926-9.
[13]	Han S, Lin M, Liu M, et al. Prevalence,trends,and geographic distribution of human papillomavirus infection in Chinese women:a summative analysis of 2 728 321 cases[J]. BMC Med, 2025, 23(1):158. doi:10.1186/s12916-025-03975-6.
[14]	Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-1337. doi:10.1007/s00404-020-05787-w.
[15]	Wang M, Liang H, Yan Y, et al. Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China:a systematic literature review[J]. Hum Vaccin Immunother, 2024, 20(1):2343192. doi:10.1080/21645515.2024.2343192.
[16]	Boon S S, Xia C, Lim J Y, et al. Human papillomavirus 58 E7 T20I/G63S variant isolated from an East Asian population possesses high oncogenicity[J]. J Virol, 2020, 94(8):e00090-e00020. doi:10.1128/JVI.00090-20.
[17]	Lai T O, Boon S S, Law P T, et al. Oncogenicitiy comparison of human papillomavirus type 52 E6 variants[J]. J Gen Virol, 2019, 100(3):484-496. doi:10.1099/jgv.0.001222.
[18]	Al-Shibli K, Nguyen D T, Mohammed H, et al. Genotype-specific HPV E6/E7 mRNA triage improves risk stratification and reduces referrals in DNA-positive ASC-US/LSIL:a real-world cohort from Nordland,Norway[J]. Pathogens, 2026, 15(2):178. doi:10.3390/pathogens15020178.
[19]	Downham L, Jaafar I, Rol M L, et al. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions:a systematic literature review and meta-analysis[J]. Br J Cancer, 2024, 130(4):517-525. doi:10.1038/s41416-023-02490-w.
[20]	Xu F, Ran T, Wei Q, et al. Diagnostic value of HPV E6/E7 mRNA in screening for cervical intraepithelial neoplasia grade 2 or worse:a systematic review and meta-analysis[J]. Oncol Lett, 2024, 27(5):231. doi:10.3892/ol.2024.14364.
[21]	Mathews C S, Sargent A, Cuschieri K, et al. HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening:comparison of test characteristics on three self-sampling devices[J]. Br J Cancer, 2025, 133(5):665-673. doi:10.1038/s41416-025-03102-5.
[22]	Granados R, Duarte J A, Luján D R, et al. RNA extended interventional nucleic acid longitudinal study:clinical performance of Aptima messenger RNA HPV testing in cervical cancer screening with a 9-year follow-up[J]. Cancer Cytopathol, 2024, 132(12):757-767. doi:10.1002/cncy.22895.
[23]	Bruno M T, Cassaro N, Vitale S G, et al. Possible role of negative human papillomavirus E6/E7 mRNA as a predictor of regression of cervical intraepithelial neoplasia 2 lesions in hr-HPV positive women[J]. Virol J, 2022, 19(1):95. doi:10.1186/s12985-022-01822-1.
[24]	Sørbye S, Falang B M, Antonsen M, et al. Genotype-specific HPV mRNA triage improves CIN2+ detection efficiency compared to cytology:a population-based study of HPV DNA-positive women[J]. Pathogens, 2025, 14(8):749. doi:10.3390/pathogens14080749.
[25]	Zhao C, Li M, Chen R, et al. Comparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes:a systematic review and meta-analysis[J]. Syst Rev, 2026, 15(1):53. doi:10.1186/s13643-025-02947-4.
[26]	Carcea F, Daniilidis A, Vavoulidis E, et al. A cohort retrospective study of high-risk HPV recurrence in Greek women after cervical lesion treatment through detection of viral E6/E7 mRNA expression[J]. J BUON, 2020, 25(1):99-107.
[27]	Loayza A, Hernandez A, Rodriguez A M, et al. HPV E6/E7 mRNA testing in the follow-up of HPV-vaccinated patients after treatment for high-grade cervical intraepithelial neoplasia[J]. Vaccines(Basel), 2025, 13(8):823. doi:10.3390/vaccines13080823.
[28]	董伟, 刘勇, 李淑霞, 等. 妊娠期宫颈高级别鳞状上皮内病变的进展转归及对妊娠结局的影响[J]. 中华围产医学杂志, 2020, 23(5):330-337.
	Dong W, Liu Y, Li S X, et al. Prognosis of cervical high-grade squamous intraepithelial lesion in pregnancy and its effect on pregnancy outcome[J]. Chin J Perinat Med, 2020, 23(5):330-337. doi:10.3760/cma.j.cn113903-20190416-00265.
[29]	杨咏梅, 王凤英, 廖秦平, 等. 高危型人乳头瘤病毒E6/E7 mRNA在妊娠期高级别宫颈病变中的应用研究[J]. 北京医学, 2022, 44(4):287-291.
	Yang Y M, Wang F Y, Liao Q P, et al. Application of HR-HPV E6 and E7 mRNA detection in the management of high grade cervical lesions during pregnancy[J]. Beijing Med J, 2022, 44(4):287-291. doi:10.15932/j.0253-9713.2022.04.001.
[30]	胡晓军, 尤小燕, 周颖. HPV E6/E7 mRNA联合年龄在宫颈癌筛查HPV-DNA阳性分流中的作用研究[J]. 医药论坛杂志, 2024, 45(23):2493-2497.
	Hu X J, You X Y, Zhou Y. Study on role of HPV E6/E7 mRNA combined with age in screening HPV-DNA positive shunt for cervical cancer[J]. Journal of Medical Forum, 2024, 45(23):2493-2497. doi:10.20159/j.cnki.jmf.2024.23.007.
[31]	Bruno M T, Cavallaro A G, Sudano M C, et al. Role of endocervical curettage in detecting CIN2 + in postmenopausal women with persistent high-risk HPV and type 3 transformation zone[J]. BMC Cancer, 2025, 25(1):1486. doi:10.1186/s12885-025-14868-5.
[32]	Richter K L, Snyman L C, Dreyer G, et al. Aptima HPV E6/E7 mRNA and cytology cross-sectional performance as primary screening tests for detection of high-grade cervical lesions in HIV positive and negative women in South Africa[J]. J Med Screen, 2025, 32(3):133-140. doi:10.1177/09691413251317926.
[33]	Ratnam S, Coutlee F, Fontaine D, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer[J]. J Clin Microbiol, 2010, 48(8):2779-2785. doi:10.1128/JCM.00382-10.
[34]	Nkwinika V V, Amissah K A, Rakgole J N, et al. APTIMA mRNA vs. DNA-based HPV assays:analytical performance insights from a resource-limited South African setting[J]. Int J Mol Sci, 2025, 26(15):7450. doi:10.3390/ijms26157450.
[35]	U.S. Food and Drug Administration. Summary of safety and effectiveness data:APTIMA HPV assay:PMA No. P100042[R/OL]. (2011-10-28)[2026-05-07]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100042b.pdf.
[36]	World Health Organization. Affordability of screen and treat tools for cervical cancer:Version 3[R/OL]. (2024-07-31)[2026-04-07]. https://cdn.who.int/media/docs/default-source/cervical-cancer/hpv-pricing-slides-2024.pdf.
[37]	广州市宝创生物技术有限公司. Aptima HPV E6/E7 mRNA 检测试剂盒产品介绍[EB/OL]. [2026-03-17]. https://www.ebiotron.com/cn/product/158.html.
	Guangzhou Baobio Biotechnology Co., Ltd. Product introduction of Aptima HPV E6/E7 mRNA detection kit[EB/OL]. [2026-03-17]. https://www.ebiotron.com/cn/product/158.html.
[38]	Liu T, Zhou X, Tao X, et al. Optimization of RNAscope for HPV mRNA detection in liquid-based cervical cytology samples[J]. Front Oncol, 2026, 16:1766237. doi:10.3389/fonc.2026.1766237.

HPV E6/E7 mRNA检测在宫颈癌筛查分流管理中的价值与应用策略

Stratification value and application strategies of HPV E6/E7 mRNA testing in cervical cancer screening

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 1

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李明, 金建华, 吴建亭, 王君辉, 许俊. 个性化腰垫与体膜联合固定对宫颈癌放疗患者摆位精度及稳定性的影响[J]. 天津医药, 2026, 54(3): 299-302.
[2]	刘星辰, 王芳, 沈勇. Decorin和Mimecan在宫颈癌中的表达及其对预后评估的影响[J]. 天津医药, 2025, 53(6): 578-583.
[3]	王彩丽, 王蕊, 郭丽宁. 高危型HPV阳性宫颈癌组织中ALKBH5和PAK5的表达水平及临床意义[J]. 天津医药, 2025, 53(4): 355-359.
[4]	田友军, 谭正武, 杨柯, 彭剑敏, 陈红桃, 黄志平. 多序列MRI影像组学对局部晚期宫颈鳞癌同步放化疗疗效的预测价值[J]. 天津医药, 2025, 53(2): 213-218.
[5]	杨艳艳, 王平, 伊雪, 彭金柱, 何宇, 张文宇, 陈磊, 阿孜亚. 北京市中关村地区13 105例女性高危型HPV感染及基因分型流行病学分析[J]. 天津医药, 2025, 53(10): 1086-1090.
[6]	孙俊杰, 郭素杰, 李洪林, 岳莹莹, 王兴芬. 光动力疗法与子宫颈环形电切术治疗宫颈上皮内瘤变2级的疗效对比[J]. 天津医药, 2024, 52(5): 509-513.
[7]	王倩倩, 李婷芳, 王峰. CHD4调控端粒功能促进宫颈癌HeLa细胞生长的机制研究[J]. 天津医药, 2023, 51(9): 909-914.
[8]	龙颖, 黄芳依, 韦有生. NGF/TrkA轴对宫颈癌SiHa细胞增殖、凋亡和侵袭的影响[J]. 天津医药, 2023, 51(8): 809-813.
[9]	王玉宁, 宋聚星, 田志刚, 郝国荣, 申浩. 白皮杉醇调控miR-106b-5p/RUNX3轴对宫颈癌细胞迁移及侵袭的影响[J]. 天津医药, 2023, 51(8): 814-819.
[10]	杜晨旭, 公建庄, 张艺, 张适, 燕巍, 谢林森△. LINC01123通过miR-449a调控HGF/c-MET通路参与宫颈癌发生发展的分子机制[J]. 天津医药, 2022, 50(1): 46-52.
[11]	甄娟 , 刘玉东 , 宋春红 , 吴莎 , 毕学杰 . RNA结合蛋白Musashi2与宫颈鳞状细胞癌关系的研究[J]. 天津医药, 2021, 49(8): 842-846.
[12]	智艳芳, 张婷, 刘慧, 曾宪旭, 班振英, 张威. DNMT1通过下调SOX1表达参与宫颈癌生长和转移的机制研究[J]. 天津医药, 2021, 49(12): 1250-1255.
[13]	宋鹏霞, 李群锋, 曹焰晖, 姚水洪. miR-422a靶向激肽释放酶-4抑制宫颈癌细胞的增殖、迁移与侵袭[J]. 天津医药, 2021, 49(10): 1031-1037.
[14]	金燕, 王静, 庞淼, 张晓雪, 刘开扬△. 新城疫病毒通过影响细胞微丝骨架对宫颈癌HeLa细胞增殖、迁移和侵袭的抑制作用#br# [J]. 天津医药, 2021, 49(1): 1-6.
[15]	王月波, 廖宗慧, 李杭△. 扩散加权成像兴趣区选择在宫颈癌分化程度、淋巴结转移及脉管受侵中的对比研究#br#[J]. 天津医药, 2021, 49(1): 79-84.